Sandoz Plugs Ophthalmology Gap With Coherus Ranibizumab Deal

Deal Includes $170m Upfront; Coherus Pushing Into Novel Oncology Space

Sandoz has truly spread its wings since separating from Novartis, striking its first post-spinoff acquisition agreement by taking the Lucentis biosimilar Cimerli from Coherus BioSciences, which is moving in a different strategic direction.

M&A
• Source: Shutterstock

Sandoz is set to fill a major gap in its blossoming biosimilars portfolio and bolster its ophthalmology offering by acquiring Coherus BioSciences’ Formycon-partnered Cimerli (ranibizumab-eqrn) biosimilar to Genentech’s Lucentis in the US for $170m upfront, plus inventory costs.

The deal, which boosts Sandoz as it anticipates filings for a biosimilar to the cornerstone anti-VEGF eye-disease biologic Eylea (aflibercept),...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.